Page last updated: 2024-10-31

nafamostat and Glaucoma

nafamostat has been researched along with Glaucoma in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuda, Y1
Nakahara, T1
Ueda, K1
Mori, A1
Sakamoto, K1
Ishii, K1

Other Studies

1 other study available for nafamostat and Glaucoma

ArticleYear
Effect of nafamostat on N-methyl-D-aspartate-induced retinal neuronal and capillary degeneration in rats.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:12

    Topics: Animals; Basement Membrane; Benzamidines; Capillaries; Diabetic Neuropathies; Excitatory Amino Acid

2012